Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
This study has been terminated.
( slow accrual and financial resource limitation )
Study NCT00476554   Information provided by Cyclacel Pharmaceuticals, Inc.

First Received on May 19, 2007.   Last Updated on November 7, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cutaneous T-cell Lymphoma (CTCL)
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Sapacitabine
Sponsors listed in this trial
Cyclacel Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services